InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,565.90
(
1.03%
)
US TECH 100
19,847.60
(
1.05%
)
Dow Jones
39,360.52
(
0.13%
)
Brent Oil
86.45
(
-1.01%
)
Bitcoin
56,559.37
(
-0.74%
)
Post# of 252491
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119981
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 203053

Tuesday, 08/02/2016 9:31:15 AM

Tuesday, August 02, 2016 9:31:15 AM

Post# of 252491
AMGN/ADXS PR:

http://finance.yahoo.com/news/amgen-advaxis-enter-global-cancer-120000771.html

Under the terms of the agreement, Amgen receives exclusive worldwide rights to develop and commercialize ADXS-NEO. Amgen will make an upfront payment to Advaxis of $40 million and purchase $25 million of Advaxis common stock.

Amgen will be fully responsible for funding clinical and commercial activities. Advaxis will lead the clinical development of ADXS-NEO through proof-of-concept, retain manufacturing responsibilities, and receive development, regulatory and sales milestone payments of up to $475 million and potential high single digit to mid-double digit royalty payments based on worldwide sales.

ADXS is +24%.

CC at 9:30am ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up